Highlights • The majority of teprotumumab-treated patients experienced otologic symptoms. • Most otologic symptoms resolved after therapy, with the exception of hearing loss. • Baseline hearing loss portends higher risk…
Purpose To summarize the current evidence on COVID-19 vaccine-associated ocular adverse events. Design Narrative literature review. Methods The literature search was conducted in August 2021 using 4 electronic databases: MEDLINE,…
PURPOSE To investigate 5-year outcomes in eyes initially treated with aflibercept or bevacizumab for macular edema due to central retinal or hemiretinal vein occlusion. METHODS Long-term follow-up (LTF) after a…
PURPOSE The blue light hazard is the experimental finding that blue light is highly toxic to the retina (photic retinopathy), in brief abnormally intense exposures, including sungazing or vitreoretinal endoillumination….
PURPOSE The purpose of this study is to establish consensus among experts on outcomes and methods to be used in clinical trials to assess adverse effects of anti-glaucomatous eye drops….
W e appreciate Toprak’s interest in our work . The purpose of our study was to do our best to provide a real-life clinical scenario to determine the impact of…
Highlights • Preloaded Descemet membrane endothelial keratoplasty (DMEK) with endothelium-inward must be preserved for less than 4 days to avoid endothelial cell loss and early postoperative complications. • Rebubbling rate…
I read the study by Asroui and associates with great interest. The authors evaluated the influence of corneal epithelial thickness mapping on refractive surgery candidacy screening among 100 patients in…
W e appreciate the opportunity of responding to Hammond and Renzi-Hammond’s comments on our AJO perspective. The writers suggest that we impugn all commercial support for research. Rather, we drew…
T his journal does not allow the space, figures, and referencing necessary to adequately respond to the factual errors and logical fallacies (eg, insufficient natural light exposure is not a…
